How do you pay?

How to pay the least

Ask for the cash price

Zydelig

We didn’t find one.

  1. Ask your pharmacy for Zydelig’s cash price, and one or two other pharmacies too.
  2. Zydelig’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameZydelig
Authorized genericidelalisib
Regular genericidelalisib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Zydelig?
The original
–
–

Brand nameThe maker’s card

Zydelig Co-pay Savings Program

Savings card from Gilead Sciences

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $5 a prescription

Sign up on gilead.com 

Or call 1-866-664-5327.

In the maker’s words

“Eligible patients could pay as little as $5 per prescription.”

From the maker’s offer on gilead.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Zydelig itself, from the same company, sold without the brand name, and usually for less. For now Zydelig is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

Zydelig is a kinase inhibitor indicated for the treatment of patients with:

  • Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.

Limitations of use:

Zydelig is not indicated and is not recommended for first-line treatment of any patient, including patients with CLL, small lymphocytic lymphoma (SLL), follicular lymphoma (FL), and other indolent non-Hodgkin lymphomas.

Zydelig is not indicated and is not recommended in combination with bendamustine and rituximab, or in combination with rituximab for the treatment of patients with FL, SLL, and other indolent non-Hodgkin lymphomas.

Source: the FDA label for Zydelig (Gilead Sciences, Inc.), September 10, 2026. Full label on DailyMed 

Good to know